President Joe Biden intends to seek more additional funding from Congress, just weeks after he told lawmakers that roughly $40 billion were needed to prop up Ukraine, replenish America’s federal disaster funds, and boost law enforcement at the crisis-riddled US-Mexico border.
This time, however, Biden will ask for funds that will cover the development of another new COVID-19 vaccine.
"I signed off this morning on a proposal we have to present to the Congress a request for additional funding for a new vaccine that is necessary, that works... It will likely be recommended that everybody get it no matter whether they’ve gotten it before or not," Biden said on Friday.
The last time Joe Biden, currently vacationing in the Lake Tahoe area, asked Congress for money to address COVID-19 was in November 2022. At the time, he unsuccessfully attempted to get lawmakers to greenlight a $9 billion request.
Ever since Republicans took control of the US House of Representatives in January, many of them have demanded spending cuts, and pledged to oppose blank checks for Kiev. Accordingly, the White House is going to have a tough uphill fight getting supplementary spending through Congress in fall.
The new demand for funds will come as COVID-19 hospital admissions appear to be on the rise in the US. Hospitalizations stood at 9,056 people for the week ending July 29, which is a surge of around 12 percent from the previous week. Some regions have event gone as far as to reignite the debate around bringing back mask mandates.
Amid the uptick, new vaccines containing the XBB.1.5 version of the Omicron strain are currently in the pipeline, being developed by drugmakers like Pfizer, Novavax, and Moderna. However, according to health authorities in the US, this particular variant is declining, with Omicron subvariant known as EG.5 - dubbed "Eris" - becoming the dominant one. The subvariant has been designated a variant under monitoring by the World Health Organization (WHO), but not yet marked as a variant of interest or of concern. Data from the US Centers for Disease Control and Prevention (CDC) on August 5 showed that EG.5 was responsible for between 14-21 percent of new COVID-19 cases in the US. Accordingly, the Omicron virus' continuing mutation will likely necessitate updated vaccines, looking ahead. But the new shots will still be effective, health experts have been cited as saying, as EG.5 shares enough common characteristics with the XBB-series of subvariants.
All three abovementioned pharmaceutical companies have been working on vaccine boosters targeting the XBB-series of Omicron subvariants in line with a June directive by the US Food and Drug Administration, and are still waiting for official FDA approval of their vaccines.